Familial prostate cancer

Familial prostate cancer (also known as hereditary prostate cancer or HPC) refers to prostate cancer that clusters in families due to inherited genetic susceptibility. It is defined by the occurrence of prostate cancer in three or more first-degree relatives, in three successive generations, or in two relatives diagnosed before age 55. Familial prostate cancer accounts for approximately 5-10% of all prostate cancer cases and up to 40% of early-onset cases. The disease affects the prostate gland, a walnut-sized organ in the male reproductive system that produces seminal fluid. Several genetic loci have been implicated, including HOXB13 (particularly the G84E variant), BRCA1, BRCA2, and loci on chromosomes 1q24-25 (HPC1/RNASEL), 1q42-43, Xq27-28 (HPCX), and 17p (HPC2/ELAC2), among others. The condition demonstrates significant genetic heterogeneity, meaning multiple genes can contribute to familial risk. Clinical features of familial prostate cancer are similar to sporadic prostate cancer but tend to present at an earlier age, typically 6-7 years earlier than non-hereditary cases. Symptoms may include difficulty urinating, decreased force of urinary stream, blood in urine or semen, bone pain (if metastatic), erectile dysfunction, and pelvic discomfort. However, early-stage disease is often asymptomatic and detected through prostate-specific antigen (PSA) screening. Men with a strong family history are recommended to begin screening discussions with their physicians at age 40-45, earlier than the general population. Treatment options for familial prostate cancer mirror those for sporadic prostate cancer and depend on the stage and grade of the tumor. These include active surveillance for low-risk disease, radical prostatectomy, radiation therapy (external beam or brachytherapy), androgen deprivation therapy, chemotherapy, and newer targeted therapies. Notably, patients with BRCA2 mutations may have more aggressive disease and may benefit from PARP inhibitors such as olaparib. Genetic counseling and testing are recommended for affected families to identify at-risk individuals and guide screening and management strategies.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Familial prostate cancer